Recurrence of extreme serum analytes in consecutive pregnancies and association with obstetrical outcomes*

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Journal of Maternal-Fetal & Neonatal Medicine

• Publication date

  2019-01-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14767058.2017.1371695PMID 28838266
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Failure of physiologic transformation of spiral arteries, endothelial and trophoblast cell activation, and acute atherosis in the basal plate of the placenta

  2017cited by this paper
• Population based biomarker screening and the development of severe preeclampsia in California

  2015cited by this paper
• Population-based biomarker screening and the development of severe preeclampsia in California.

  2014cited by this paper
• First trimester screening cannot predict adverse outcomes yet

  2014cited by this paper
• Maternal serum analytes as predictors of IUGR with different degrees of placental vascular dysfunction

  2014cited by this paper
• The "Great Obstetrical Syndromes" are associated with disorders of deep placentation.

  2011cited by this paper
• First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes.

  2010cited by this paper
• First‐trimester biochemical markers of aneuploidy and the prediction of small‐for‐gestational age fetuses

  2008cited by this paper
• First‐trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery

  2008cited by this paper
• Low levels of maternal serum PAPP‐A in the first trimester and the risk of pre‐eclampsia

  2008cited by this paper
• Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: Systematic review and meta-analysis

  2008cited by this paper
• Genetics of preeclampsia: paradigm shifts

  2006cited by this paper
• Effect on down syndrome screening performance of adjusting for marker levels in a previous pregnancy

  2006cited by this paper
• Quad Screen as a Predictor of Adverse Pregnancy Outcome

  2005cited by this paper
• Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.

  2004cited by this paper
• First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).

  2004cited by this paper
• Prenatal screening for Down syndrome: the problem of recurrent false‐positives

  2004cited by this paper
• Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisited

  2002cited by this paper
• Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies

  2001cited by this paper
• Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome.

  1999cited by this paper
• The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A.

  1999cited by this paper
• Maternal serum screening for Down's syndrome taking account of the result in a previous pregnancy

  1994cited by this paper
• Amnioinfusion: An Aid in the Ultrasonographic Evaluation of Severe Oligohydramnios in Pregnancy

  1992cited by this paper
• Increased maternal serum alpha‐fetoprotein and human chorionic gonadotropin in compromised pregnancies other than for neural tube defects or Down syndrome

  1992cited by this paper
• Pre-eclampsia and the placenta

  1991cited by this paper
• Current topic: pre-eclampsia and the placenta.

  1991cited by this paper
• Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome

  1988cited by this paper
• Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome

  1988cited by this paper
• Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities

  1987cited by this paper
• An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities.

  1984cited by this paper
• Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome.

  1984cited by this paper
• An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalities

  1984cited by this paper
• Elevated maternal serum alpha-fetoprotein levels associated with breakdown in fetal-maternal-placental barrier.

  1983cited by this paper
• NORMAL BIOLOGY OF α‐FETOPROTEIN

  1975cited by this paper
• Normal biology of alpha-fetoprotein.

  1975cited by this paper

• No citing papers are available for this paper.